Skip to main content
Top
Published in: World Journal of Pediatrics 5/2019

01-10-2019 | Dyslipidemia | Original Article

Impact of dyslipidemia on estimated glomerular filtration rate in apparently healthy children and adolescents: the CASPIAN-V study

Authors: Mohammad Moafi, Farahnak Assadi, Ramin Heshmat, Mehri Khoshhali, Mostafa Qorbani, Mohammad E. Motlagh, Razieh Dashti, Majzoubeh Taheri, Roya Kelishadi

Published in: World Journal of Pediatrics | Issue 5/2019

Login to get access

Abstract

Background

Chronic kidney disease (CKD) is a leading risk factor for development of cardiovascular disease (CVD). Dyslipidemia is also known as risk factor for CVD development. However, the association of dyslipidemia with glomerular injury among healthy children and adolescents remains controversial. We aimed to investigate the relationship between estimated glomerular filtration rate (eGFR) and lipid profile risk factors among healthy children and adolescents.

Methods

In this nationwide survey, 3808 participants (1992 males, 1816 females), aged 7–18 years, were selected by cluster random sampling method from 30 provinces in Iran. Body mass index (BMI) and systolic and diastolic blood pressures were measured. Blood samples were obtained for serum creatinine, fasting blood glucose, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) determinations. GFR was estimated using Schwartz equation.

Results

Girls had higher eGFR than boys (P = 0.04). In a multiple regression analysis, eGFR demonstrated a positive correlation with systolic blood pressure, BMI, fasting glucose, TC, HDL-C, and TG. By the analysis of covariance, TC, HDL-C, and TG showed a negative correlation with eGFR after adjustments for BMI, systolic and diastolic blood pressures, and fasting glucose (OR = 0.56, 95% CI = 0.29–0.89).

Conclusion

The study showed that dyslipidemia is associated with reduced eGFR among the healthy children and adolescents.
Literature
1.
go back to reference Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–72.CrossRef Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382:260–72.CrossRef
2.
go back to reference Assadi F. The epidemic of chronic kidney disease: the danger of skepticism. J Nephropathol. 2012;15:61–4.CrossRef Assadi F. The epidemic of chronic kidney disease: the danger of skepticism. J Nephropathol. 2012;15:61–4.CrossRef
3.
go back to reference Mills KT, Xu Y, Zhang W, Bundy JD, Chen C-S, Kelly TN, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int. 2015;88:950–7.CrossRef Mills KT, Xu Y, Zhang W, Bundy JD, Chen C-S, Kelly TN, et al. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int. 2015;88:950–7.CrossRef
4.
go back to reference Anaverka NS, McMurray JJ, Velazques EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–95.CrossRef Anaverka NS, McMurray JJ, Velazques EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285–95.CrossRef
5.
go back to reference Bazyluk A, Malyszko J, Zbroch E. Cardiovascular risk in chronic kidney disease: what is new in the pathogenesis and treatment? Postgrad Med. 2018;130:461–9.CrossRef Bazyluk A, Malyszko J, Zbroch E. Cardiovascular risk in chronic kidney disease: what is new in the pathogenesis and treatment? Postgrad Med. 2018;130:461–9.CrossRef
6.
go back to reference Weaver DJ, Mitsnefes M. Cardiovascular disease in children and adolescents with kidney disease. Semin Nephrolol. 2018;38:559–69.CrossRef Weaver DJ, Mitsnefes M. Cardiovascular disease in children and adolescents with kidney disease. Semin Nephrolol. 2018;38:559–69.CrossRef
7.
go back to reference Hager MR, Narla AD, Tannock LR. Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord. 2017;18:29–40.CrossRef Hager MR, Narla AD, Tannock LR. Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord. 2017;18:29–40.CrossRef
8.
go back to reference Bermudez-Lopez M, Arroyo D, Bertriu A, Masana L, Fernandez E, Valdivielso JM. New perspectives on CKD-induced dyslipidemia. Expert Opin Ther Targets. 2017;21:967–76.CrossRef Bermudez-Lopez M, Arroyo D, Bertriu A, Masana L, Fernandez E, Valdivielso JM. New perspectives on CKD-induced dyslipidemia. Expert Opin Ther Targets. 2017;21:967–76.CrossRef
9.
go back to reference Khandelwal P, Murugan V, Hari S, Lakshmy R, Hari P, Bagga A. Dyslipidemia: carotid intima-media thickness and endothelial dysfunction in children with chronic kidney disease. Pediatr Nephrol. 2016;31:1313–20.CrossRef Khandelwal P, Murugan V, Hari S, Lakshmy R, Hari P, Bagga A. Dyslipidemia: carotid intima-media thickness and endothelial dysfunction in children with chronic kidney disease. Pediatr Nephrol. 2016;31:1313–20.CrossRef
10.
go back to reference Khurana M, Silverstein DM. Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease. Pediatr Nephrol. 2015;30:2073–84.CrossRef Khurana M, Silverstein DM. Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease. Pediatr Nephrol. 2015;30:2073–84.CrossRef
11.
go back to reference Hu PJ, Wu MY, Lin TC, Wu YC, Su SL, Lu KC, et al. Effect of statin on renal function in chronic kidney disease patients. Sci Rep. 2018;8:6276.CrossRef Hu PJ, Wu MY, Lin TC, Wu YC, Su SL, Lu KC, et al. Effect of statin on renal function in chronic kidney disease patients. Sci Rep. 2018;8:6276.CrossRef
12.
go back to reference Milolasevic I, Zutellia M, Mavrinac V, Orlic L. Dyslipidemia in chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017;10:35–45.CrossRef Milolasevic I, Zutellia M, Mavrinac V, Orlic L. Dyslipidemia in chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017;10:35–45.CrossRef
13.
go back to reference Koulouridis E, Georgealidis K, Kostimpa I, Koulouridis I, Krokida A, Houliara D. Metabolic syndrome risk factors and estimated glomerular filtration rate among children and adolescents. Pediatr Nephrol. 2010;25:491–8.CrossRef Koulouridis E, Georgealidis K, Kostimpa I, Koulouridis I, Krokida A, Houliara D. Metabolic syndrome risk factors and estimated glomerular filtration rate among children and adolescents. Pediatr Nephrol. 2010;25:491–8.CrossRef
14.
go back to reference Kuma A, Uchino B, Kawashima M, Enta K, Tamura M, Outsuji Y, et al. Impact of low-density lipoprotein cholesterol in estimated glomerular filtration rate in apparently healthy young to middle-aged men. Clin Exp Nephrol. 2018;22:15–27. CrossRef Kuma A, Uchino B, Kawashima M, Enta K, Tamura M, Outsuji Y, et al. Impact of low-density lipoprotein cholesterol in estimated glomerular filtration rate in apparently healthy young to middle-aged men. Clin Exp Nephrol. 2018;22:15–27. CrossRef
15.
go back to reference Ahadi Z, Bahreynian M, Qorbani M, Heshmat R, Motlagh ME, Shafiee G, et al. Association of anthropometric measures and cardio-metabolic risk factors in normal-weight children and adolescents: the CASPIAN-V study. J Pediatr Endocrinol Metab. 2018;31:747–54.CrossRef Ahadi Z, Bahreynian M, Qorbani M, Heshmat R, Motlagh ME, Shafiee G, et al. Association of anthropometric measures and cardio-metabolic risk factors in normal-weight children and adolescents: the CASPIAN-V study. J Pediatr Endocrinol Metab. 2018;31:747–54.CrossRef
16.
go back to reference Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics. 2002;109:45–60.CrossRef Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics. 2002;109:45–60.CrossRef
17.
go back to reference Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 30140:e20171904.CrossRef Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. (2017) Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 30140:e20171904.CrossRef
18.
go back to reference Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629–37.CrossRef Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629–37.CrossRef
19.
go back to reference Cases A, Coll E. Dyslipidemia and progression of renal disease in chronic renal disease patients. Kidney Int Suppl. 2005;99:S87–93.CrossRef Cases A, Coll E. Dyslipidemia and progression of renal disease in chronic renal disease patients. Kidney Int Suppl. 2005;99:S87–93.CrossRef
20.
go back to reference Hirano T, Sakaue T, Misaki A, Murayama S, Takahashi T, Okada K, et al. Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy; comparison with apoprotein C-III. Kidney Int. 2003;63:217–27.CrossRef Hirano T, Sakaue T, Misaki A, Murayama S, Takahashi T, Okada K, et al. Very low-density lipoprotein-apoprotein CI is increased in diabetic nephropathy; comparison with apoprotein C-III. Kidney Int. 2003;63:217–27.CrossRef
21.
go back to reference Wj Cain, Milar JS, Himebauch AS, Tietge UJ, Maugeais C, Usher D, et al. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein. J Lipid Res. 2005;46:2681–91.CrossRef Wj Cain, Milar JS, Himebauch AS, Tietge UJ, Maugeais C, Usher D, et al. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein. J Lipid Res. 2005;46:2681–91.CrossRef
22.
go back to reference Vazirin ND, Wang XQ, Liang K. Secondary hyperparathyroidism down regulates lipoprotein lipase expression in chronic renal failure. Am J Phys. 1997;273:F925–30. Vazirin ND, Wang XQ, Liang K. Secondary hyperparathyroidism down regulates lipoprotein lipase expression in chronic renal failure. Am J Phys. 1997;273:F925–30.
23.
go back to reference Assadi F. The growing epidemic of hypertension among children and adolescents: a challenging road ahead. Pediatr Cardiol. 2012;33:1013–20.CrossRef Assadi F. The growing epidemic of hypertension among children and adolescents: a challenging road ahead. Pediatr Cardiol. 2012;33:1013–20.CrossRef
24.
go back to reference Assadi F. Childhood hypertension: a problem of epidemic proportion. Int J Prev Med. 2012;25:473–80. Assadi F. Childhood hypertension: a problem of epidemic proportion. Int J Prev Med. 2012;25:473–80.
25.
go back to reference Kelishadi R, Gorbani M, Assadi F, Motlag ME, Djalalnia S, Shahsavari A, et al. Glomerular hyperfiltration as a predictor of cardiometabolic risk factors among children and adolescents The childhood and adolescent surveillance and prevention of adult-V study. Int J Prev Med. 2018;9:33.CrossRef Kelishadi R, Gorbani M, Assadi F, Motlag ME, Djalalnia S, Shahsavari A, et al. Glomerular hyperfiltration as a predictor of cardiometabolic risk factors among children and adolescents The childhood and adolescent surveillance and prevention of adult-V study. Int J Prev Med. 2018;9:33.CrossRef
26.
go back to reference Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1-full report. J Clin Lipidol. 2015;9:129–69.CrossRef Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1-full report. J Clin Lipidol. 2015;9:129–69.CrossRef
27.
go back to reference Jellinger PS, Handelsman Y, Rosenbilts PD, Bloomgarden ZT, Fonesca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease-executive summary. Endocr Pract. 2017;23(Suppl 2):1–87.CrossRef Jellinger PS, Handelsman Y, Rosenbilts PD, Bloomgarden ZT, Fonesca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease-executive summary. Endocr Pract. 2017;23(Suppl 2):1–87.CrossRef
28.
go back to reference Safdar O, Al sharif S, Kari A. Pediatric CKD and cardiovascular disease. Cardiovasc Hematol Disord Drug Targets. 2014;14:177–84.CrossRef Safdar O, Al sharif S, Kari A. Pediatric CKD and cardiovascular disease. Cardiovasc Hematol Disord Drug Targets. 2014;14:177–84.CrossRef
29.
go back to reference Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A, et al. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014;25:1825–33.CrossRef Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A, et al. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014;25:1825–33.CrossRef
30.
go back to reference Assadi F. Strategies to reduce the incidence of chronic kidney disease in children: a time of action. J Nephrol. 2013;26:41–7.CrossRef Assadi F. Strategies to reduce the incidence of chronic kidney disease in children: a time of action. J Nephrol. 2013;26:41–7.CrossRef
31.
go back to reference Apple LJ, Champagne CM, Harsha DW, Cooper LS, Obarzaneck E, Elmer PJ, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289:2083–93. Apple LJ, Champagne CM, Harsha DW, Cooper LS, Obarzaneck E, Elmer PJ, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA. 2003;289:2083–93.
Metadata
Title
Impact of dyslipidemia on estimated glomerular filtration rate in apparently healthy children and adolescents: the CASPIAN-V study
Authors
Mohammad Moafi
Farahnak Assadi
Ramin Heshmat
Mehri Khoshhali
Mostafa Qorbani
Mohammad E. Motlagh
Razieh Dashti
Majzoubeh Taheri
Roya Kelishadi
Publication date
01-10-2019
Publisher
Springer Singapore
Published in
World Journal of Pediatrics / Issue 5/2019
Print ISSN: 1708-8569
Electronic ISSN: 1867-0687
DOI
https://doi.org/10.1007/s12519-019-00270-2

Other articles of this Issue 5/2019

World Journal of Pediatrics 5/2019 Go to the issue